PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharming Group N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026
$9.11−0.25 (-2.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2277.5
- Dividend yield
- –
Pharming Group N.V. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| RUCONEST | $317.92M | $252.24M | $227.13M | $205.62M | $198.87M | – | – | 84.5% | +26.0% |
| JOENJA | $58.21M | $44.96M | $18.18M | $0 | $0 | – | – | 15.5% | +29.5% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $361.75M | $287.15M | $239.11M | $200.08M | $193.42M | $202.68M | $182.29M | 96.2% | +26.0% |
| Europe and RoW | $14.39M | $10.05M | $6.21M | $5.54M | $4.93M | – | – | 3.8% | +43.1% |
| RoW | – | – | – | $616.00K | $519.00K | $1.26M | $1.45M | – | – |
| Europe | – | – | – | $4.92M | $4.93M | $8.23M | $5.65M | – | – |
From the segment and revenue-disaggregation notes of Pharming's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.